The Eli Lilly Alzheimer's Phase 2 clinical trial shows promising results and success in slowing the decline seen in dementia patients. The New York Times reported on the success of the small clinical trial by Eli Lilly and Company January 11, 2021. Neurology Diagnostics proudly announces that we are a top enrollment site for the Eli Lilly's Alzheimer's Phase 2 clinical trial, enrolling just under 5% of the of the 272 patients studied world-wide. This is an exciting breakthrough for Alzheimer's reseach showing promising, first of its kind success in slowing Alzheimer's disease progression.
The Eli Lilly research trial studies the effects of the drug, donanemab, a monoclonal antibody that works by binding to a small part of the hard plaques in the brain made of protein or amyloid that is the hallmark of Alzheimer's disease. Patients receive the drug by infusion every 4 weeks. The Eli Lilly Alzheimer's Phase 2 clinical trial results show study participants that received the drug had a 32% reduction in the rate of decline, compared with those who took the placebo. "In 6 to 12 months, plaques were gone and stayed gone" according to Dr. Daniel Skovronsky, Eli Lilly's chief scientific officer.
Neurology Diagnostics is continuing in the next phase of the Eli Lilly trial and currently enrolling patients for a limited time. These scientific advancements exemplify our motive to remain on the leading edge of treatment giving us and our patient's hope.
As we continue forward on the path toward fighting the onset and progression of Alzheimer's disease, we are recruiting for the follow up Eli Lilly study, as well as, other Alzheimer treatment trials future studies. If you or someone you know may be interested in participating, please let us know.
